The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma (OPC) treated with intensity modulated radiation therapy (IMRT) ± systemic therapy (ST).
 
Paolo Bossi
Honoraria - Angelini; Bristol-Myers Squibb; GlaxoSmithKline; Merck; MSD Oncology; Regeneron; Sun Pharma
Consulting or Advisory Role - Angelini Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD Oncology; Sanofi/Regeneron; Sun Pharma
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD Oncology (Inst); Regeneron (Inst); Roche (Inst)
 
Riccardo Gili
No Relationships to Disclose
 
Stefano Calza
No Relationships to Disclose
 
Lisa F. Licitra
Honoraria - Adlai Nortye; ALTIS Omnia Pharma Service S.r.l.; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; AstraZeneca; Boehringer Ingelheim; Eisai; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Merck Healtcare KGaA; Merck Serono; Mirati Therapeutics; MSD; MSD; Novartis Farma S.p.a.; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences
 
Marta Maddalo
No Relationships to Disclose
 
Almalina Bacigalupo
No Relationships to Disclose
 
Liliana Belgioia
No Relationships to Disclose
 
Jon Cacicedo
No Relationships to Disclose
 
Nadia Facchinetti
No Relationships to Disclose
 
Almudena Garcia
No Relationships to Disclose
 
Marc Oliva
Honoraria - Bristol-Myers Squibb/Pfizer; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Merck KGaA; MSD Oncology; MSD Oncology
Research Funding - ALX Oncology (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - BeiGene; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Merck; MSD Oncology
 
Pierluigi Bonomo
Consulting or Advisory Role - Merck Serono; MSD; Pfizer
 
Giuseppe Sanguineti
No Relationships to Disclose
 
Pierfrancesco Franco
No Relationships to Disclose
 
Athanassios Argiris
No Relationships to Disclose
 
Amanda Psyrri
Honoraria - Astrazeneca; Bayer; BMS; Genesis Pharmaceuticals; GlaxoSmithKline; Merck Serono; merus; MSD Oncology; Pfizer; Roche; seagen
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; eTheRNA immunotherapies; GlaxoSmithKline; Merus NV; MSD Oncology; Pfizer; Seagen
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Demo Pharmaceutical; Kura Oncology; Pfizer; Pharmathen; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Ipsen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; AstraZeneca
 
Ester Orlandi
No Relationships to Disclose